Ftse Mib
33.313,63
1,23%
DAX
18.127,74
0,30%
S&P 500
5.481,38
0,15%
NASDAQ
17.862,03
0,03%
Bitcoin
64.734,00
-2,64%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ 4D Molecular Therapeutics Inc (FDMT) 4D Molecular Therapeutics Inc (FDMT) Notizie

FDMT

4D Molecular Therapeutics (FDMT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FDMT
DataOraFonteTitoloSimboloCompagnia
18/06/202414:00GlobeNewswire Inc.4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate WebcastNASDAQ:FDMT4D Molecular Therapeutics Inc
08/06/202422:30GlobeNewswire Inc.4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
07/06/202423:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
07/06/202423:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FDMT4D Molecular Therapeutics Inc
06/06/202413:30GlobeNewswire Inc.4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
04/06/202414:00GlobeNewswire Inc.4DMT Announces Presentations at Clinical Trials at the Summit 2024 MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
03/06/202414:00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
30/05/202414:00GlobeNewswire Inc.4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
24/05/202401:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
09/05/202422:05GlobeNewswire Inc.4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
07/05/202414:00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
01/05/202414:00GlobeNewswire Inc.4DMT Announces Presentations at ARVO 2024 Annual MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
28/03/202413:00GlobeNewswire Inc.4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202423:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202422:05GlobeNewswire Inc.4DMT Reports Full Year 2023 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
15/02/202402:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
12/02/202414:00GlobeNewswire Inc.4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024NASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202422:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202401:42Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
07/02/202405:27GlobeNewswire Inc.4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common StockNASDAQ:FDMT4D Molecular Therapeutics Inc
05/02/202422:35Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:FDMT4D Molecular Therapeutics Inc
05/02/202422:05GlobeNewswire Inc.4D Molecular Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:FDMT4D Molecular Therapeutics Inc
03/02/202423:00GlobeNewswire Inc.4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMDNASDAQ:FDMT4D Molecular Therapeutics Inc
29/01/202414:00GlobeNewswire Inc.4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment BurdenNASDAQ:FDMT4D Molecular Therapeutics Inc
23/01/202414:00GlobeNewswire Inc.4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung DiseaseNASDAQ:FDMT4D Molecular Therapeutics Inc
04/01/202414:00GlobeNewswire Inc.4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational UpdatesNASDAQ:FDMT4D Molecular Therapeutics Inc
03/01/202414:01GlobeNewswire Inc.4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS DiseasesNASDAQ:FDMT4D Molecular Therapeutics Inc
21/12/202318:31Dow Jones News4D Molecular Shares Rise on FDA Designation for Wet AMD DrugNASDAQ:FDMT4D Molecular Therapeutics Inc
21/12/202314:00GlobeNewswire Inc.4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMDNASDAQ:FDMT4D Molecular Therapeutics Inc
04/12/202314:00GlobeNewswire Inc.4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FDMT

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
MONC
Moncler
BIT
STMMI
ST Microelectronics
BIT
LDO
Leonardo
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
RACE
Ferrari NV
BIT
A2A
A2A
BIT
SRG
Snam
BIT
G
Generali
BIT
NEXI
Nexi S.p.A
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network